secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K/A
Filed at:   2022-01-14T23:59:59+00:00
Accession:  0001104659-22-004497
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 9.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

VYNE director Rex Bright dies; board appoints LePore, Sandoval; MST sale yields $20M upfront
--------------------------------------------------------------------------------

- Director Rex Bright passed away on Jan 11, 2022; he chaired Compensation Committee and served on Audit Committee.
- Board appointed Patrick LePore to Audit Committee and Elisabeth Sandoval as chair of Compensation Committee on Jan 14, 2022.
- MST franchise sold to Journey Medical for $20M upfront, $5M in 1 year, plus up to $450M in milestone payments.
- Pro forma balance sheet shows cash of $67.9M after sale; discontinued operations eliminate product sales revenues.
- Pro forma net loss from continuing ops for nine months ended Sep 30, 2021 was $37.1M, down from $61.8M historical.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922004497/0001104659-22-004497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922004497/tm222963d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-004497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer